Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure

Table 2

Comparison of characteristics of responders and nonresponders to CD34+ cell therapy. Values are presented as , number of patients (percent), or median (IQR) for NT-proBNP.

	Nonresponders ()	Responders ()
Age (y)			0.32
Male gender (%)	15 (85)	36 (84)	0.96
Nonischemic CMP (%)	13 (72)	29 (67)	0.67
LVEF (%)
Baseline			<0.05
3 months			<0.05
6MWT (m)			0.28
NT-proBNP (pg/mL (IQR))	3245 (1584-4336)	609 (240-1323)	<0.05
Creatinine (mmol/L)			<0.05
Bilirubin (μmol/L)			0.48
Sodium (mmol/L)			0.84
AST (μmol/L)			0.10
AF (μmol/L)			0.60
gGT (μmol/L)			0.68
RDW (%)			0.01
Leukocytes (×109)			0.85
Hemoglobin (g/L)			0.44
Platelet count (×109)			0.89
Medical management
ACEI/ARB	18 (100)	42 (100)	/
Beta blockers	18 (100)	42 (100)	/
MRA	18 (100)	42 (100)	/
Diuretic	12 (67)	21 (48)	0.24
Aspirin	7 (39)	26 (60)	0.13
Galectin-3 levels (ng/mL)
Baseline			0.80
3 months			<0.05

ICMP: ischemic cardiomyopathy; DCMP: nonischemic cardiomyopathy; LVEF: left ventricular ejection fraction; 6MWT: 6-minute walk test; AST: aspartate transaminase; AF: alkaline phosphatase; gGT: γ-glutamyltranspeptidase; RDW: red cell distribution width; ACEI: angiotensin convertase inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist.